Plant 5 will be operational in April and the CDMO is moving forward with plans for the construction of Plant 6 to “maintain the world’s No. 1 manufacturing capacity.”
CEO Greg Behar said recent investments and partnerships have significantly expanded the global CDMO’s capacity in key areas such as pre-filled syringes and lyophilization.
Part of Vetter’s Center for Visual Inspection and Logistics, construction of the 22,500-square-meter extension began in late 2024, with completion expected by 2028.
The investment supports the construction of an R&D and manufacturing hub to advance Entos’ Fusogenix PLV drug delivery platform and expand Canadian biomanufacturing capacity.
Located at its global headquarters in Craigavon, the new 100,000-square-foot facility augments Almac’s capabilities in the manufacture of oral dose treatments.
The 225,000-square-foot addition to its Durham plant includes data analytics, generative AI, 3D printing, as well as a training center equipped with a digital twin.
William Blair analyst Andy Hsieh in a note to investors said the comprehensive agreement mitigates supply chain risk for Viking’s VK2735 dual GLP-1/GIP agonist.
Chief Financial Officer Lucas Montarce said on Monday that the drugmaker’s increase in production capacity from its four future sites in the United States will take years.
Europe depends on Asia for 60% to 80% of its pharmaceutical supply, according to the health ministers, who want to see the European Union adopt the Critical Medicines Act.
The collaboration advances contract development and manufacturing organization services for nanoparticle-based drugs in Taiwan, Japan, and global markets.
The new center will support customers looking to reduce their emissions, from upstream supply chain emissions to downstream low environmental impact products.
The company said the organic sales decline of 9.4% was mainly driven by a customer adjusting its supply chain, as well as the loss of pandemic-related sales last year.
The project is part of the company’s more than $1 billion investment over the next three years to enhance its peptide production across Europe and the U.S.
The expansion reinforces Axplora’s role as the supplier of 40% of the world’s marketed antibody-drug conjugates and 50% of FDA-approved ADCs, according to the company.
CEO Albert Bourla said that Pfizer’s mitigation strategy is to leverage its 13 production sites in the U.S. if President Donald Trump imposes tariffs on pharmaceuticals.
Despite a “volatile” February due to uncertainty in the U.S. and abroad, CEO Marc Casper contends the company is “well positioned” to navigate the geopolitical environment.
The Government Accountability Office found that the FDA continues to face significant vacancies among investigators who conduct inspections in foreign countries.
The vaccine company and contract manufacturer are building a dedicated suite at Lonza’s Ibex Dedicate Biopark in Visp, Switzerland to support Vaxcyte’s PCV franchise.
The agency’s inspection identified multiple deficiencies in the company’s quality control procedures, equipment maintenance, and record-keeping practices.
The company reported full-year results including a 7.9% decrease in operating revenue due to a lagging contract development and manufacturing organization business.
